Charles River Laboratories International, Inc.

Symbol: CRL

NYSE

230.09

USD

Market price today

  • 26.5377

    P/E Ratio

  • 2.7835

    PEG Ratio

  • 11.82B

    MRK Cap

  • 0.00%

    DIV Yield

Charles River Laboratories International, Inc. (CRL) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.36%

Operating Profit Margin

0.14%

Net Profit Margin

0.11%

Return on Assets

0.05%

Return on Equity

0.13%

Return on Capital Employed

0.08%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Mr. James C. Foster J.D.
Full-time employees:20400
City:Wilmington
Address:251 Ballardvale Street
IPO:2000-06-23
CIK:0001100682

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.357% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.140%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.108%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.055% return, is a testament to Charles River Laboratories International, Inc.'s adeptness in optimizing resource deployment. Charles River Laboratories International, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.129%. Furthermore, the proficiency of Charles River Laboratories International, Inc. in capital utilization is underscored by a remarkable 0.080% return on capital employed.

Stock Prices

Charles River Laboratories International, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $237.62, while its low point bottomed out at $226.44. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Charles River Laboratories International, Inc.'s stock market.

Liquidity Ratios

Analyzing CRL liquidity ratios reveals its financial health of the firm. The current ratio of 174.71% gauges short-term asset coverage for liabilities. The quick ratio (116.67%) assesses immediate liquidity, while the cash ratio (34.25%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio174.71%
Quick Ratio116.67%
Cash Ratio34.25%

Profitability Ratios

CRL profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.36% underscores its earnings before tax deductions. The effective tax rate stands at 17.91%, revealing its tax efficiency. The net income per EBT, 81.20%, and the EBT per EBIT, 95.46%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 13.99%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.36%
Effective Tax Rate17.91%
Net Income per EBT81.20%
EBT per EBIT95.46%
EBIT per Revenue13.99%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.75, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding117
Days of Inventory Outstanding50
Operating Cycle119.78
Days of Payables Outstanding18
Cash Conversion Cycle102
Receivables Turnover5.22
Payables Turnover20.37
Inventory Turnover7.31
Fixed Asset Turnover2.05
Asset Turnover0.50

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 13.69, and free cash flow per share, 8.04, depict cash generation on a per-share basis. The cash per share value, 6.36, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.17, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share13.69
Free Cash Flow per Share8.04
Cash per Share6.36
Operating Cash Flow Sales Ratio0.17
Free Cash Flow to Operating Cash Flow Ratio0.59
Cash Flow Coverage Ratio0.23
Capital Expenditure Coverage Ratio2.42
Dividend Paid and Capex Coverage Ratio2.42

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 37.76%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.85, we discern the balance between debt and equity financing. The long-term debt to capitalization, 45.82%, and total debt to capitalization, 45.82%, ratios shed light on its capital structure. An interest coverage of 8.55 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio37.76%
Debt Equity Ratio0.85
Long Term Debt to Capitalization45.82%
Total Debt to Capitalization45.82%
Interest Coverage8.55
Cash Flow to Debt Ratio0.23
Company Equity Multiplier2.24

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 80.61, provides a glimpse into top-line earnings distributed across each share. Net income per share, 9.27, reflects the portion of profit attributed to each share. The book value per share, 70.21, represents the net asset value distributed per share, while the tangible book value per share, -5.86, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share80.61
Net Income Per Share9.27
Book Value Per Share70.21
Tangible Book Value Per Share-5.86
Shareholders Equity Per Share70.21
Interest Debt Per Share71.14
Capex Per Share-6.22

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 3.86%, indicates top-line expansion, while the gross profit growth, 2.73%, reveals profitability trends. EBIT growth, -5.18%, and operating income growth, -5.18%, offer insights into operational profitability progression. The net income growth, -2.39%, showcases bottom-line expansion, and the EPS growth, -3.13%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth3.86%
Gross Profit Growth2.73%
EBIT Growth-5.18%
Operating Income Growth-5.18%
Net Income Growth-2.39%
EPS Growth-3.13%
EPS Diluted Growth-2.74%
Weighted Average Shares Growth0.82%
Weighted Average Shares Diluted Growth0.29%
Operating Cash Flow Growth10.37%
Free Cash Flow Growth23.89%
10-Year Revenue Growth per Share230.18%
5-Year Revenue Growth per Share70.56%
3-Year Revenue Growth per Share36.60%
10-Year Operating CF Growth per Share207.69%
5-Year Operating CF Growth per Share45.10%
3-Year Operating CF Growth per Share21.03%
10-Year Net Income Growth per Share330.15%
5-Year Net Income Growth per Share96.24%
3-Year Net Income Growth per Share26.02%
10-Year Shareholders Equity Growth per Share422.95%
5-Year Shareholders Equity Growth per Share155.56%
3-Year Shareholders Equity Growth per Share64.53%
Receivables Growth3.72%
Inventory Growth48.65%
Asset Growth7.79%
Book Value per Share Growth19.87%
Debt Growth-1.00%
SGA Expenses Growth12.44%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 14,899,672,800, captures the company's total value, considering both debt and equity. Income quality, 1.42, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 48.31%, indicates the value of non-physical assets, and capex to operating cash flow, -46.58%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value14,899,672,800
Income Quality1.42
Intangibles to Total Assets48.31%
Capex to Operating Cash Flow-46.58%
Capex to Revenue-7.71%
Capex to Depreciation-101.40%
Stock-Based Compensation to Revenue1.74%
Graham Number120.98
Return on Tangible Assets11.20%
Graham Net Net-68.01
Working Capital553,580,000
Tangible Asset Value-300,098,000
Net Current Asset Value-2,927,341,000
Invested Capital1
Average Receivables766,382,500
Average Payables187,426,000
Average Inventory318,034,000
Days Sales Outstanding69
Days Payables Outstanding23
Days of Inventory On Hand53
ROIC7.18%
ROE0.13%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.25, and the price to book ratio, 3.25, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.87, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 28.57, and price to operating cash flows, 16.80, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.25
Price to Book Ratio3.25
Price to Sales Ratio2.87
Price Cash Flow Ratio16.80
Price Earnings to Growth Ratio2.78
Enterprise Value Multiple9.90
Price Fair Value3.25
Price to Operating Cash Flow Ratio16.80
Price to Free Cash Flows Ratio28.57
Price to Tangible Book Ratio3.37
Enterprise Value to Sales3.61
Enterprise Value Over EBITDA14.44
EV to Operating Cash Flow21.79
Earnings Yield3.92%
Free Cash Flow Yield3.02%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Charles River Laboratories International, Inc. (CRL) on the NYSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 26.538 in 2024.

What is the ticker symbol of Charles River Laboratories International, Inc. stock?

The ticker symbol of Charles River Laboratories International, Inc. stock is CRL.

What is company IPO date?

IPO date of Charles River Laboratories International, Inc. is 2000-06-23.

What is company current share price?

Current share price is 230.090 USD.

What is stock market cap today?

The market cap of stock today is 11815075482.000.

What is PEG ratio in 2024?

The current 2.784 is 2.784 in 2024.

What is the number of employees in 2024?

In 2024 the company has 20400.